368 related articles for article (PubMed ID: 36307193)
1. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.
Oikonomou EK; Spatz ES; Suchard MA; Khera R
Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193
[TBL] [Abstract][Full Text] [Related]
2. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
[TBL] [Abstract][Full Text] [Related]
3. Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial.
Rapp SR; Gaussoin SA; Sachs BC; Chelune G; Supiano MA; Lerner AJ; Wadley VG; Wilson VM; Fine LJ; Whittle JC; Auchus AP; Beddhu S; Berlowitz DR; Bress AP; Johnson KC; Krousel-Wood M; Martindale-Adams J; Miller EC; Rifkin DE; Snyder JK; Tamariz L; Wolfgram DF; Cleveland ML; Yang M; Nichols LO; Bryan RN; Reboussin DM; Williamson JD; Pajewski NM;
Lancet Neurol; 2020 Nov; 19(11):899-907. PubMed ID: 33098800
[TBL] [Abstract][Full Text] [Related]
4. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Nazarzadeh M; Bidel Z; Canoy D; Copland E; Bennett DA; Dehghan A; Davey Smith G; Holman RR; Woodward M; Gupta A; Adler AI; Wamil M; Sattar N; Cushman WC; McManus RJ; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
Lancet Diabetes Endocrinol; 2022 Sep; 10(9):645-654. PubMed ID: 35878651
[TBL] [Abstract][Full Text] [Related]
5. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
[TBL] [Abstract][Full Text] [Related]
7. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration
Lancet; 2021 Sep; 398(10305):1053-1064. PubMed ID: 34461040
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration
Lancet; 2021 May; 397(10285):1625-1636. PubMed ID: 33933205
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefit of systolic blood pressure within the target range among patients with or without diabetes mellitus: a propensity score-matched analysis of two randomized clinical trials.
Li C; Chen K; Shi G; Shi R; Wu Z; Yuan X; Watson V; Jiang Z; Mai H; Yang T; Wang D; Chen T
BMC Med; 2022 Jun; 20(1):208. PubMed ID: 35718771
[TBL] [Abstract][Full Text] [Related]
11. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials.
Beddhu S; Greene T; Boucher R; Cushman WC; Wei G; Stoddard G; Ix JH; Chonchol M; Kramer H; Cheung AK; Kimmel PL; Whelton PK; Chertow GM
Lancet Diabetes Endocrinol; 2018 Jul; 6(7):555-563. PubMed ID: 29685860
[TBL] [Abstract][Full Text] [Related]
12. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
Zhang L; Sun X; Liao L; Zhang S; Zhou H; Zhong X; Zhuang X; Liao X
J Clin Hypertens (Greenwich); 2019 Dec; 21(12):1813-1820. PubMed ID: 31670874
[TBL] [Abstract][Full Text] [Related]
14. Clinical Value of Predicting Individual Treatment Effects for Intensive Blood Pressure Therapy.
Duan T; Rajpurkar P; Laird D; Ng AY; Basu S
Circ Cardiovasc Qual Outcomes; 2019 Mar; 12(3):e005010. PubMed ID: 30857410
[TBL] [Abstract][Full Text] [Related]
15. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
Vaduganathan M; Claggett BL; Juraschek SP; Solomon SD
JAMA Cardiol; 2020 May; 5(5):576-581. PubMed ID: 32101262
[TBL] [Abstract][Full Text] [Related]
17. Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial.
Ghazi L; Shen J; Ying J; Derington CG; Cohen JB; Marcum ZA; Herrick JS; King JB; Cheung AK; Williamson JD; Pajewski NM; Bryan N; Supiano M; Sonnen J; Weintraub WS; Greene TH; Bress AP
JAMA Netw Open; 2023 May; 6(5):e2314443. PubMed ID: 37204788
[TBL] [Abstract][Full Text] [Related]
18. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
Attar A; Sayadi M; Jannati M
Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
[TBL] [Abstract][Full Text] [Related]
19. Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).
Sun X; Guo Y; Nie Z; Cheng J; Zhou H; Zhong X; Zhang S; Du Z; Zhuang X; Liao X
Clin Res Cardiol; 2019 Mar; 108(3):273-281. PubMed ID: 30167807
[TBL] [Abstract][Full Text] [Related]
20. Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.
Bress AP; Greene T; Derington CG; Shen J; Xu Y; Zhang Y; Ying J; Bellows BK; Cushman WC; Whelton PK; Pajewski NM; Reboussin D; Beddu S; Hess R; Herrick JS; Zhang Z; Kolm P; Yeh RW; Basu S; Weintraub WS; Moran AE;
J Am Coll Cardiol; 2021 Apr; 77(16):1977-1990. PubMed ID: 33888247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
